Literature DB >> 19503083

Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease.

Yanping Li1, Wencheng Liu, Tinmarla F Oo, Lei Wang, Yi Tang, Vernice Jackson-Lewis, Chun Zhou, Kindiya Geghman, Mikhail Bogdanov, Serge Przedborski, M Flint Beal, Robert E Burke, Chenjian Li.   

Abstract

Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic cause of Parkinson's disease. We created a LRRK2 transgenic mouse model that recapitulates cardinal features of the disease: an age-dependent and levodopa-responsive slowness of movement associated with diminished dopamine release and axonal pathology of nigrostriatal dopaminergic projection. These mice provide a valid model of Parkinson's disease and are a resource for the investigation of pathogenesis and therapeutics.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19503083      PMCID： PMC2845930          DOI： 10.1038/nn.2349

Source DB:  PubMed          Journal:  Nat Neurosci        ISSN： 1097-6256            Impact factor:   24.884


  15 in total

1.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

Authors:  M H Polymeropoulos; C Lavedan; E Leroy; S E Ide; A Dehejia; A Dutra; B Pike; H Root; J Rubenstein; R Boyer; E S Stenroos; S Chandrasekharappa; A Athanassiadou; T Papapetropoulos; W G Johnson; A M Lazzarini; R C Duvoisin; G Di Iorio; L I Golbe; R L Nussbaum
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

2.  A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease.

Authors:  Alessio Di Fonzo; Christan F Rohé; Joaquim Ferreira; Hsin F Chien; Laura Vacca; Fabrizio Stocchi; Leonor Guedes; Edito Fabrizio; Mario Manfredi; Nicola Vanacore; Stefano Goldwurm; Guido Breedveld; Cristina Sampaio; Giuseppe Meco; Egberto Barbosa; Ben A Oostra; Vincenzo Bonifati
Journal:  Lancet       Date:  2005 Jan 29-Feb 4       Impact factor: 79.321

3.  Cytochrome c release and caspase activation in traumatic axonal injury.

Authors:  A Büki; D O Okonkwo; K K Wang; J T Povlishock
Journal:  J Neurosci       Date:  2000-04-15       Impact factor: 6.167

Review 4.  Parkinson's disease: mechanisms and models.

Authors:  William Dauer; Serge Przedborski
Journal:  Neuron       Date:  2003-09-11       Impact factor: 17.173

5.  Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study.

Authors:  J E Tobin; J C Latourelle; M F Lew; C Klein; O Suchowersky; H A Shill; L I Golbe; M H Mark; J H Growdon; G F Wooten; B A Racette; J S Perlmutter; R Watts; M Guttman; K B Baker; S Goldwurm; G Pezzoli; C Singer; M H Saint-Hilaire; A E Hendricks; S Williamson; M W Nagle; J B Wilk; T Massood; J M Laramie; A L DeStefano; I Litvan; G Nicholson; A Corbett; S Isaacson; D J Burn; P F Chinnery; P P Pramstaller; S Sherman; J Al-hinti; E Drasby; M Nance; A T Moller; K Ostergaard; R Roxburgh; B Snow; J T Slevin; F Cambi; J F Gusella; R H Myers
Journal:  Neurology       Date:  2008-05-28       Impact factor: 9.910

6.  Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases.

Authors:  John E Duda; Benoit I Giasson; Meghann E Mabon; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2002-08       Impact factor: 10.422

7.  Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.

Authors:  Alexander Zimprich; Saskia Biskup; Petra Leitner; Peter Lichtner; Matthew Farrer; Sarah Lincoln; Jennifer Kachergus; Mary Hulihan; Ryan J Uitti; Donald B Calne; A Jon Stoessl; Ronald F Pfeiffer; Nadja Patenge; Iria Carballo Carbajal; Peter Vieregge; Friedrich Asmus; Bertram Müller-Myhsok; Dennis W Dickson; Thomas Meitinger; Tim M Strom; Zbigniew K Wszolek; Thomas Gasser
Journal:  Neuron       Date:  2004-11-18       Impact factor: 17.173

8.  A common LRRK2 mutation in idiopathic Parkinson's disease.

Authors:  William P Gilks; Patrick M Abou-Sleiman; Sonia Gandhi; Shushant Jain; Andrew Singleton; Andrew J Lees; Karen Shaw; Kailash P Bhatia; Vincenzo Bonifati; Niall P Quinn; John Lynch; Daniel G Healy; Janice L Holton; Tamas Revesz; Nicholas W Wood
Journal:  Lancet       Date:  2005 Jan 29-Feb 4       Impact factor: 79.321

9.  The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region.

Authors:  J Biernat; E M Mandelkow; C Schröter; B Lichtenberg-Kraag; B Steiner; B Berling; H Meyer; M Mercken; A Vandermeeren; M Goedert; E Mandelkow
Journal:  EMBO J       Date:  1992-04       Impact factor: 11.598

10.  Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease.

Authors:  Coro Paisán-Ruíz; Shushant Jain; E Whitney Evans; William P Gilks; Javier Simón; Marcel van der Brug; Adolfo López de Munain; Silvia Aparicio; Angel Martínez Gil; Naheed Khan; Janel Johnson; Javier Ruiz Martinez; David Nicholl; Itxaso Martí Carrera; Amets Saénz Pena; Rohan de Silva; Andrew Lees; José Félix Martí-Massó; Jordi Pérez-Tur; Nick W Wood; Andrew B Singleton
Journal:  Neuron       Date:  2004-11-18       Impact factor: 17.173
View more
  235 in total

1.  The creation of transgenic pigs expressing human proteins using BAC-derived, full-length genes and intracytoplasmic sperm injection-mediated gene transfer.

Authors:  Masahito Watanabe; Mayuko Kurome; Hitomi Matsunari; Kazuaki Nakano; Kazuhiro Umeyema; Akira Shiota; Hiromitsu Nakauchi; Hiroshi Nagashima
Journal:  Transgenic Res       Date:  2011-10-25       Impact factor: 2.788

Review 2.  Axon degeneration in Parkinson's disease.

Authors:  Robert E Burke; Karen O'Malley
Journal:  Exp Neurol       Date:  2012-01-18       Impact factor: 5.330

3.  Treatment frontiers.

Authors:  Kerri Smith
Journal:  Nature       Date:  2010-08-26       Impact factor: 49.962

4.  Parkinson's disease: a model dilemma.

Authors:  M Flint Beal
Journal:  Nature       Date:  2010-08-26       Impact factor: 49.962

Review 5.  Parkinson's disease: insights from pathways.

Authors:  Mark R Cookson; Oliver Bandmann
Journal:  Hum Mol Genet       Date:  2010-04-26       Impact factor: 6.150

Review 6.  Genetically engineered mouse models of Parkinson's disease.

Authors:  Donna M Crabtree; Jianhua Zhang
Journal:  Brain Res Bull       Date:  2011-08-03       Impact factor: 4.077

7.  Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice.

Authors:  M Yue; K M Hinkle; P Davies; E Trushina; F C Fiesel; T A Christenson; A S Schroeder; L Zhang; E Bowles; B Behrouz; S J Lincoln; J E Beevers; A J Milnerwood; A Kurti; P J McLean; J D Fryer; W Springer; D W Dickson; M J Farrer; H L Melrose
Journal:  Neurobiol Dis       Date:  2015-03-31       Impact factor: 5.996

8.  Axonal pathology in hPSC-based models of Parkinson's disease results from loss of Nrf2 transcriptional activity at the Map1b gene locus.

Authors:  Christopher Czaniecki; Tammy Ryan; Morgan G Stykel; Jennifer Drolet; Juliane Heide; Ryan Hallam; Shalandra Wood; Carla Coackley; Keith Sherriff; Craig D C Bailey; Scott D Ryan
Journal:  Proc Natl Acad Sci U S A       Date:  2019-06-24       Impact factor: 11.205

9.  (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD.

Authors:  C-Y Chen; Y-H Weng; K-Y Chien; K-J Lin; T-H Yeh; Y-P Cheng; C-S Lu; H-L Wang
Journal:  Cell Death Differ       Date:  2012-04-27       Impact factor: 15.828

10.  LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity.

Authors:  Loukia Parisiadou; Jia Yu; Carmelo Sgobio; Chengsong Xie; Guoxiang Liu; Lixin Sun; Xing-Long Gu; Xian Lin; Nicole A Crowley; David M Lovinger; Huaibin Cai
Journal:  Nat Neurosci       Date:  2014-01-26       Impact factor: 24.884
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.